Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II

John R. Ingram; Martina Porter; Raj Chovatiya; Evangelos J. Giamarellos-Bourboulis; Falk G. Bechara; Hideki Fujita; Wayne Gulliver; Edward Muller; Muhammad Bari; Robert Rolleri; Rob Byerly; Joslyn S. Kirby

doi:10.25251/skin.8.supp.396

Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II

John R. Ingram, Martina Porter, Raj Chovatiya, Evangelos J. Giamarellos-Bourboulis, Falk G. Bechara, Hideki Fujita, Wayne Gulliver, Edward Muller, Muhammad Bari, Robert Rolleri, Rob Byerly, Joslyn S. Kirby

Department of Dermatology

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	S396
Journal	SKIN: Journal of Cutaneous Medicine
Volume	8
Issue number	2
DOIs	https://doi.org/10.25251/skin.8.supp.396
State	Published - Mar 18 2024

All Science Journal Classification (ASJC) codes

Dermatology

Access to Document

10.25251/skin.8.supp.396

Cite this

Ingram, J. R., Porter, M., Chovatiya, R., Giamarellos-Bourboulis, E. J., Bechara, F. G., Fujita, H., Gulliver, W., Muller, E., Bari, M., Rolleri, R., Byerly, R., & Kirby, J. S. (2024). Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II. SKIN: Journal of Cutaneous Medicine, 8(2), S396. https://doi.org/10.25251/skin.8.supp.396

@article{c53fcf8259534dc4ba8b24cbc62398ef,

title = "Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II",

author = "Ingram, {John R.} and Martina Porter and Raj Chovatiya and Giamarellos-Bourboulis, {Evangelos J.} and Bechara, {Falk G.} and Hideki Fujita and Wayne Gulliver and Edward Muller and Muhammad Bari and Robert Rolleri and Rob Byerly and Kirby, {Joslyn S.}",

year = "2024",

month = mar,

day = "18",

doi = "10.25251/skin.8.supp.396",

language = "English (US)",

volume = "8",

pages = "S396",

journal = "SKIN: Journal of Cutaneous Medicine",

issn = "2574-1624",

publisher = "National Society for Cutaneous Medicine",

number = "2",

}

Ingram, JR, Porter, M, Chovatiya, R, Giamarellos-Bourboulis, EJ, Bechara, FG, Fujita, H, Gulliver, W, Muller, E, Bari, M, Rolleri, R, Byerly, R & Kirby, JS 2024, 'Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II', SKIN: Journal of Cutaneous Medicine, vol. 8, no. 2, pp. S396. https://doi.org/10.25251/skin.8.supp.396

Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II. / Ingram, John R.; Porter, Martina; Chovatiya, Raj et al.
In: SKIN: Journal of Cutaneous Medicine, Vol. 8, No. 2, 18.03.2024, p. S396.

Research output: Contribution to journal › Comment/debate › peer-review

TY - JOUR

T1 - Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa

T2 - Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II

AU - Ingram, John R.

AU - Porter, Martina

AU - Chovatiya, Raj

AU - Giamarellos-Bourboulis, Evangelos J.

AU - Bechara, Falk G.

AU - Fujita, Hideki

AU - Gulliver, Wayne

AU - Muller, Edward

AU - Bari, Muhammad

AU - Rolleri, Robert

AU - Byerly, Rob

AU - Kirby, Joslyn S.

PY - 2024/3/18

Y1 - 2024/3/18

UR - http://www.scopus.com/inward/record.url?scp=85188288094&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85188288094&partnerID=8YFLogxK

U2 - 10.25251/skin.8.supp.396

DO - 10.25251/skin.8.supp.396

M3 - Comment/debate

AN - SCOPUS:85188288094

SN - 2574-1624

VL - 8

SP - S396

JO - SKIN: Journal of Cutaneous Medicine

JF - SKIN: Journal of Cutaneous Medicine

IS - 2

ER -

Ingram JR, Porter M, Chovatiya R, Giamarellos-Bourboulis EJ, Bechara FG, Fujita H et al. Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II. SKIN: Journal of Cutaneous Medicine. 2024 Mar 18;8(2):S396. doi: 10.25251/skin.8.supp.396

Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Cite this